Furthermore, it was reported that the PPAR-γ agonists rosiglitazone and pioglitazone target pituitary tumors in vitro and in vivo in Cushing's disease [11, 12, 22, 34, 35]. The gene discussed is PPARG; the disease is pituitary tumor.